• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

优化 I 类组蛋白去乙酰化酶 PROTAC 揭示了 HDAC1/2 的降解对于诱导癌细胞凋亡和细胞停滞至关重要。

Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.

机构信息

Leicester Institute of Structural and Chemical Biology, School of Chemistry, University of Leicester, Leicester LE1 7RH, U.K.

Department of Molecular and Cell Biology, University of Leicester, Leicester LE1 7RH, U.K.

出版信息

J Med Chem. 2022 Apr 14;65(7):5642-5659. doi: 10.1021/acs.jmedchem.1c02179. Epub 2022 Mar 16.

DOI:10.1021/acs.jmedchem.1c02179
PMID:35293758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9014412/
Abstract

Class I histone deacetylase (HDAC) enzymes 1, 2, and 3 organize chromatin as the catalytic subunits within seven distinct multiprotein corepressor complexes and are established drug targets. We report optimization studies of benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTACs) and for the first time describe transcriptome perturbations resulting from these degraders. By modifying the linker and VHL ligand, we identified PROTACs , , and with submicromolar DC values for HDAC1 and/or HDAC3 in HCT116 cells. A hook effect was observed for HDAC3 that could be negated by modifying the position of attachment of the VHL ligand to the linker. The more potent HDAC1/2 degraders correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells. We demonstrate that HDAC1/2 degradation by PROTACs correlates with enhanced global gene expression and apoptosis, important for the development of more efficacious HDAC therapeutics with reduced side effects.

摘要

I 类组蛋白去乙酰化酶 (HDAC) 酶 1、2 和 3 作为七个不同的多蛋白核心抑制复合物中的催化亚基组织染色质,是既定的药物靶点。我们报告了基于苯甲酰胺的 Von Hippel-Lindau (VHL) E3 连接酶蛋白水解靶向嵌合体 (PROTAC) 的优化研究,并首次描述了这些降解剂导致的转录组扰动。通过修饰接头和 VHL 配体,我们鉴定出了 PROTACs 、 和 ,它们在 HCT116 细胞中对 HDAC1 和/或 HDAC3 的 DC 值低于亚毫摩尔。观察到了 HDAC3 的钩状效应,通过修饰 VHL 配体与接头的连接位置可以消除该效应。更有效的 HDAC1/2 降解剂与更多的总差异表达基因相关,并增强 HCT116 细胞中的细胞凋亡。我们证明,PROTAC 对 HDAC1/2 的降解与增强的全局基因表达和细胞凋亡相关,这对于开发更有效、副作用更小的 HDAC 治疗药物非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/530987d1d297/jm1c02179_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/1dd5ae232488/jm1c02179_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/1e932bdc58f5/jm1c02179_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/89ced697e45f/jm1c02179_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/bd8664cf9142/jm1c02179_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/57a88171bd8c/jm1c02179_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/5711f3b0e38f/jm1c02179_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/02fc2fb430a7/jm1c02179_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/121b8ee534a4/jm1c02179_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/92ee9af140be/jm1c02179_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/8ab5c1c93c8c/jm1c02179_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/530987d1d297/jm1c02179_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/1dd5ae232488/jm1c02179_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/1e932bdc58f5/jm1c02179_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/89ced697e45f/jm1c02179_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/bd8664cf9142/jm1c02179_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/57a88171bd8c/jm1c02179_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/5711f3b0e38f/jm1c02179_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/02fc2fb430a7/jm1c02179_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/121b8ee534a4/jm1c02179_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/92ee9af140be/jm1c02179_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/8ab5c1c93c8c/jm1c02179_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbab/9014412/530987d1d297/jm1c02179_0012.jpg

相似文献

1
Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.优化 I 类组蛋白去乙酰化酶 PROTAC 揭示了 HDAC1/2 的降解对于诱导癌细胞凋亡和细胞停滞至关重要。
J Med Chem. 2022 Apr 14;65(7):5642-5659. doi: 10.1021/acs.jmedchem.1c02179. Epub 2022 Mar 16.
2
Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs).新型 I 类 HDAC 蛋白水解靶向嵌合体(PROTACs)的综合转录组分析。
Biochemistry. 2023 Feb 7;62(3):645-656. doi: 10.1021/acs.biochem.2c00288. Epub 2022 Aug 10.
3
Cereblon-recruiting proteolysis targeting chimeras (PROTACs) can determine the selective degradation of HDAC1 over HDAC3.cereblon 招募的蛋白水解靶向嵌合体(PROTACs)可特异性地使 HDAC1 降解,而不降解 HDAC3。
Chem Commun (Camb). 2024 Nov 21;60(94):13879-13882. doi: 10.1039/d4cc05138f.
4
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.VHL E3 连接酶在 PROTACs 设计中的旅程:从 VHL 配体到基于 VHL 的降解剂。
Eur J Med Chem. 2024 Feb 5;265:116041. doi: 10.1016/j.ejmech.2023.116041. Epub 2023 Dec 14.
5
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes.PROTAC 介导的核心抑制复合物中 I 类组蛋白去乙酰化酶的降解。
Chem Commun (Camb). 2020 Apr 21;56(32):4476-4479. doi: 10.1039/d0cc01485k.
6
Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs. cereblon 与 vhl :使用 protacs 相互劫持 e3 连接酶。
Bioorg Med Chem. 2019 Jun 15;27(12):2466-2479. doi: 10.1016/j.bmc.2019.02.048. Epub 2019 Feb 22.
7
Vascular endothelial growth factor production is induced by histone deacetylase 1 and suppressed by von Hippel-Lindau protein in HaCaT cells.在HaCaT细胞中,血管内皮生长因子的产生由组蛋白去乙酰化酶1诱导,并被冯·希佩尔-林道蛋白抑制。
Clin Invest Med. 2012 Dec 1;35(6):E340-50. doi: 10.25011/cim.v35i6.19205.
8
Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders.首款靶向FEM1B的组蛋白去乙酰化酶降解剂的研发。
J Med Chem. 2025 Jan 23;68(2):1824-1843. doi: 10.1021/acs.jmedchem.4c02569. Epub 2025 Jan 13.
9
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present).对招募冯·希佩尔-林道(VHL)的化学物质的专利综述:用于PROTACs的E3连接酶配体与靶向蛋白质降解(2019年至今)
Expert Opin Ther Pat. 2025 Feb 6;35(3):1-42. doi: 10.1080/13543776.2024.2446232.
10
Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.同源PROTACs:VHL E3泛素连接酶的二价小分子二聚体,用于诱导自我降解。
Nat Commun. 2017 Oct 10;8(1):830. doi: 10.1038/s41467-017-00954-1.

引用本文的文献

1
Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death.利用PROTAC对1类组蛋白去乙酰化酶进行靶向降解在诱导弥漫性大B细胞淋巴瘤(DLBCL)细胞死亡方面非常有效。
EJHaem. 2025 Aug 12;6(4):e70127. doi: 10.1002/jha2.70127. eCollection 2025 Aug.
2
Synthetic and structure-activity studies of SP2577 and TCP towards LSD1 targeting PROTACs.针对靶向LSD1的PROTAC的SP2577和TCP的合成及构效关系研究。
RSC Med Chem. 2025 Aug 5. doi: 10.1039/d5md00420a.
3
Advancing Design Strategy of PROTACs for Cancer Therapy.用于癌症治疗的PROTACs的先进设计策略

本文引用的文献

1
Chemo-proteomics exploration of HDAC degradability by small molecule degraders.通过小分子降解剂对 HDAC 降解能力的化学生物组学探索。
Cell Chem Biol. 2021 Oct 21;28(10):1514-1527.e4. doi: 10.1016/j.chembiol.2021.07.002. Epub 2021 Jul 26.
2
Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).通过蛋白酶体靶向嵌合体(PROTAC)诱导组蛋白去乙酰化酶 3(HDAC3)的蛋白降解。
Eur J Med Chem. 2020 Dec 15;208:112800. doi: 10.1016/j.ejmech.2020.112800. Epub 2020 Sep 6.
3
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
MedComm (2020). 2025 Jun 25;6(7):e70258. doi: 10.1002/mco2.70258. eCollection 2025 Jul.
4
Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function.一种潜在血液系统恶性肿瘤疗法的发现:靶向非酶功能的选择性强效组蛋白去乙酰化酶7(HDAC7)蛋白酶体靶向嵌合体降解剂
Acta Pharm Sin B. 2025 Mar;15(3):1659-1679. doi: 10.1016/j.apsb.2025.01.021. Epub 2025 Jan 30.
5
New and Effective Inhibitor of Class I HDACs, Eimbinostat, Reduces the Growth of Hematologic Cancer Cells and Triggers Apoptosis.新型高效I类组蛋白去乙酰化酶抑制剂艾姆比诺司他可降低血液癌细胞的生长并引发凋亡。
Pharmaceutics. 2025 Mar 25;17(4):416. doi: 10.3390/pharmaceutics17040416.
6
Epigenetic drugs in cancer therapy.用于癌症治疗的表观遗传药物。
Cancer Metastasis Rev. 2025 Feb 26;44(1):37. doi: 10.1007/s10555-025-10253-7.
7
Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy.针对具有细胞类型特异性功能的细胞内蛋白质进行癌症免疫治疗。
Life Med. 2023 Jun 17;2(3):lnad019. doi: 10.1093/lifemedi/lnad019. eCollection 2023 Jun.
8
Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders.首款靶向FEM1B的组蛋白去乙酰化酶降解剂的研发。
J Med Chem. 2025 Jan 23;68(2):1824-1843. doi: 10.1021/acs.jmedchem.4c02569. Epub 2025 Jan 13.
9
Cereblon-recruiting proteolysis targeting chimeras (PROTACs) can determine the selective degradation of HDAC1 over HDAC3.cereblon 招募的蛋白水解靶向嵌合体(PROTACs)可特异性地使 HDAC1 降解,而不降解 HDAC3。
Chem Commun (Camb). 2024 Nov 21;60(94):13879-13882. doi: 10.1039/d4cc05138f.
10
PROTACs Targeting Epigenetic Proteins.靶向表观遗传蛋白的PROTACs
Acta Mater Med. 2023 Oct 26;2(4):409-429. doi: 10.15212/amm-2023-0039. Epub 2023 Dec 6.
发现组蛋白去乙酰化酶 3(HDAC3)特异性 PROTAC 分子。
Chem Commun (Camb). 2020 Aug 25;56(68):9866-9869. doi: 10.1039/d0cc03243c.
4
PROTACs: An Emerging Therapeutic Modality in Precision Medicine.蛋白水解靶向嵌合体(PROTACs):精准医学中的一种新兴治疗模式。
Cell Chem Biol. 2020 Aug 20;27(8):998-1014. doi: 10.1016/j.chembiol.2020.07.020. Epub 2020 Aug 13.
5
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.三十年 HDAC 抑制剂:2020 年的新视角和新认识。
J Med Chem. 2020 Nov 12;63(21):12460-12484. doi: 10.1021/acs.jmedchem.0c00830. Epub 2020 Jul 16.
6
Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.招募冯·希佩尔-林道(VHL)E3泛素连接酶的选择性组蛋白去乙酰化酶6(HDAC6)降解剂的开发
ACS Med Chem Lett. 2020 Mar 18;11(4):575-581. doi: 10.1021/acsmedchemlett.0c00046. eCollection 2020 Apr 9.
7
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes.PROTAC 介导的核心抑制复合物中 I 类组蛋白去乙酰化酶的降解。
Chem Commun (Camb). 2020 Apr 21;56(32):4476-4479. doi: 10.1039/d0cc01485k.
8
Mechanism of Crosstalk between the LSD1 Demethylase and HDAC1 Deacetylase in the CoREST Complex.LSD1 去甲基酶和 CoREST 复合物中 HDAC1 脱乙酰酶的串扰机制。
Cell Rep. 2020 Feb 25;30(8):2699-2711.e8. doi: 10.1016/j.celrep.2020.01.091.
9
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.蛋白水解靶向嵌合体作为治疗方法和生物发现工具。
Cell. 2020 Apr 2;181(1):102-114. doi: 10.1016/j.cell.2019.11.031. Epub 2020 Jan 16.
10
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.通过利用弱结合亲和力 VHL E3 连接酶配体发现高效雄激素受体(AR)的 PROTAC 降解剂。
J Med Chem. 2019 Dec 26;62(24):11218-11231. doi: 10.1021/acs.jmedchem.9b01393. Epub 2019 Dec 5.